Clinical trial
Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.
NCT02398604 is registered in ClinicalTrials.gov with Longeveron Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.
- Lead sponsor
- Longeveron Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- April 30, 2015
- Completion date
- March 31, 2019
- Enrollment
- 5 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.